Government ShutdownSkin in the GameI've Always Wondered ...How We Survive

Loading...

0:00
0% played
Power Marketplace’s public service journalism 💙 Give Now
Stories Tagged as

Biogen

Medicare rejected a controversial Alzheimer's drug. Participants still ended up paying for it.

by Lily Jamali
Oct 24, 2022
Medicare raised premiums late last year in preparation to cover the drug Aduhelm. Ultimately, Medicare rejected coverage of the drug, with limited exceptions.
Biogen initially priced its Alzheimer’s treatment drug at $56,000 a year. That figure was factored in when Medicare set Part B premiums late last year.
Dominick Reuter/AFP via Getty Images
ListenLISTEN
HTML EMBED:
COPY
EMBED EMBED
Share Now on:
SHARE
Subscribe Using:
SUBSCRIBE SUBSCRIBE

Medicare proposes limiting coverage of controversial Alzheimer's drug

by Lily Jamali
Jan 13, 2022
Government insurer won't cover Aduhelm's $28,000-a-year price tag except for clinical trials.
A sign for biotechnology company, Biogen, Inc. is seen on a building in Cambridge, Massachusetts.
DOMINICK REUTER/AFP via Getty Images
ListenLISTEN
HTML EMBED:
COPY
EMBED EMBED
Share Now on:
SHARE
Subscribe Using:
SUBSCRIBE SUBSCRIBE

Who will end up paying the price for Biogen's new Alzheimer's drug?

by Kimberly Adams
Jun 18, 2021
The cost of the newly approved treatment will be about $56,000 a year, much of it paid for by Medicare.
Biogen’s new Alzheimer's treatment drug, Aduhelm, has an annual sticker price of $56,000.
Dominick Reuter/AFP via Getty Images
ListenLISTEN
HTML EMBED:
COPY
EMBED EMBED
Share Now on:
SHARE
Subscribe Using:
SUBSCRIBE SUBSCRIBE

This is NOT a paywall. 

Marketplace is community-funded public service journalism. Give in any amount that works for you – what matters is that you give today. 

 

Get Yours Today!